Polyneuropathies
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.
Subtype terms (7)
More specific conditions that are subtypes of Polyneuropathies in the MeSH hierarchy.
- Alcoholic Neuropathy
- Hereditary Sensory and Autonomic Neuropathies
3 drugs (2 approved, 1 experimental)
- Hereditary Sensory and Motor Neuropathy
4 drugs (2 approved, 2 experimental)
- Paraneoplastic Polyneuropathy
3 drugs approved
- POEMS Syndrome
12 drugs (7 approved, 5 experimental)
- Polyradiculoneuropathy
25 drugs (17 approved, 8 experimental)
- Tangier Disease
1 drug experimental
Drugs by status
Approved for this indication (4)
Phase 4 trials (7)
Phase 3 trials (7)
Phase 2 trials (6)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (22)
- CSL Behring
- Astellas
- Gilead Sciences
- Pfizer
- Analgesic Solutions
- Nycomed
- Otsuka
- Aarhus University
- Cardiovascular Institute of the South Clinical Research Corporation
- Cancer Research Network
- University of Kansas
- University of Southern Denmark
- University of Toronto
- Aalborg University
- University of Copenhagen
- University of Turku
- CHU AMBROISE PARE
- University of Santo Tomas
- University of Paris
- European Commission
- Lundbeck
- University of Helsinki
Organization Involved with Phase 3 Indications (45)
- Meda
- Foldrx
- Eisai
- Grunenthal
- Merck
- Merck KGaA
- Grifols
- Alnylam Pharmaceuticals
- GlaxoSmithKline
- Ionis Pharmaceuticals, Inc.
- Laboratoire français de Fractionnement et de Biotechnologies
- Nihon Pharmaceutical Co., Ltd
- NovaMed Pharmaceuticals Inc.
- Polysan, Ltd.
- National Institute of Neurological Disorders and Stroke (NINDS)
- University Health Network, Toronto
- Boston University
- Eastern Virginia Medical School
- Federal University of Rio Grande do Sul
- Nanjing Medical University
- Thammasat University
- Utrecht University
- University of Bern
- University of Bordeaux
- Mayo Clinic
- Columbia University
- Food and Drug Administration
- CHU Henri Mondor
- University of Amsterdam
- University of Limoges
- +15 more
Organization Involved with Phase 2 Indications (40)
- AbbVie
- Takeda
- Mitsubishi
- Bristol-Myers Squibb
- Forest Laboratories
- Sanofi
- Leadiant Biosciences, Inc.
- Mallinckrodt
- Mundipharma
- Arvelle
- SOM Biotech SL
- The Institute for Diabetes Discovery, LLC
- Creative Peptides Sweden Inc.
- National Cancer Institute (NCI)
- University of London
- University of Washington
- Hoosier Cancer Research Network
- Loyola University
- Northwestern University
- Oregon Health and Science University
- Seoul National University
- University of Guadalajara
- Stony Brook University
- Vanderbilt University
- University of Vienna
- MedDay Pharmaceuticals
- Karolinska Institute
- Government of Korea
- Mitsubishi Tanabe
- Ruhr University Bochum
- +10 more
Organization Involved with Phase 1 Indications (14)
- Biogen
- Medy-Tox
- Ilkos Therapeutic Inc.
- Hebei University
- China Academy of Chinese Medical Sciences
- Zhengzhou University
- Anhui College of Traditional Chinese Medicine
- Liaoning Hospital of Traditional Chinese Medicine
- Catholic University of Korea
- University of Texas at Houston
- Biotest Pharmaceuticals
- National Bank of Austria
- Hubei University of Chinese Medicine
- Intellia Therapeutics
Organization Involved with Other Experimental Indications (7)